SG11201903954WA - Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder - Google Patents

Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Info

Publication number
SG11201903954WA
SG11201903954WA SG11201903954WA SG11201903954WA SG11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA SG 11201903954W A SG11201903954W A SG 11201903954WA
Authority
SG
Singapore
Prior art keywords
international
prophylaxis
treatment
blood coagulation
coagulation disorder
Prior art date
Application number
SG11201903954WA
Inventor
Sabine Pestel
Elmar Raquet
Thomas Weimer
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of SG11201903954WA publication Critical patent/SG11201903954WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 May 2018 (17.05.2018) WIPO I PCT D IV SID o III uo IIIII Ho mil Imo VII IE (10) International Publication Number WO 2018/087271 Al (51) International Patent Classification: A61K 38/36 (2006.01) A61P 7/04 (2006.01) A61K 38/37 (2006.01) A61K 36/36 (2006.01) C07K 14/755 (2006.01) A61K 36/37 (2006.01) (21) International Application Number: PCT/EP2017/078840 (22) International Filing Date: 10 November 2017 (10.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16198497.6 11 November 2016 (11.11.2016) EP (71) Applicant: CSL BEHRING RECOMBINANT FACILI- TY AG [CH/CH]; Wankdorfstrasse 10, 3014 Bern (CH). (72) Inventors: PESTEL, Sabine; Stuempelstal 19, 35041 Mar- burg (DE). RAQUET, Elmar; Wilhelm-Tischbein-Strasse 12, 35066 Frankenberg (DE). WEIMER, Thomas; Richard-Wagner-Strasse 8, 35075 Gladenbach (DE). (74) Agent: LUDWIG, Holger et al.; Emil-von-Behring- Strasse 76, 35041 Marburg (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) N (54) Title: TRUNCATED VON WILLEBRAND FACTOR POLYPEPTIDES FOR EXTRAVASCULAR ADMINISTRATION IN el THE TREATMENT OR PROPHYLAXIS OF A BLOOD COAGULATION DISORDER *t (57) : The invention pertains to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment or prophylaxis of a blood coagulation disorder, said treatment or prophylaxis comprising administering the recombinant polypeptide and a Factor VIII protein (FVIII) extravascular to a subject having a blood coagulation disorder, wherein said recombinant 1-1 polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the recombinant polypeptide to be administered to the f'1 FVIII to be administered is higher than 50.
SG11201903954WA 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder SG11201903954WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16198497 2016-11-11
PCT/EP2017/078840 WO2018087271A1 (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Publications (1)

Publication Number Publication Date
SG11201903954WA true SG11201903954WA (en) 2019-05-30

Family

ID=57389201

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912768YA SG10201912768YA (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
SG11201903954WA SG11201903954WA (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912768YA SG10201912768YA (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Country Status (12)

Country Link
US (1) US11890327B2 (en)
EP (1) EP3538134B1 (en)
JP (1) JP2020504082A (en)
KR (1) KR20190073576A (en)
CN (1) CN110381986B (en)
AU (1) AU2017358865A1 (en)
CA (1) CA3043397A1 (en)
DK (1) DK3538134T3 (en)
ES (1) ES2908008T3 (en)
SG (2) SG10201912768YA (en)
TW (1) TW201828974A (en)
WO (1) WO2018087271A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190375822A1 (en) 2018-05-18 2019-12-12 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CN114072420A (en) * 2019-07-04 2022-02-18 康诺贝林伦瑙有限公司 Truncated Von Willebrand Factor (VWF) for increasing the in vitro stability of factor VIII
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
KR102647642B1 (en) * 2021-05-04 2024-03-15 (주)케어젠 Peptides having blood coagulation activity and use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (en) 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403764B (en) * 1996-03-15 1998-05-25 Immuno Ag STABLE FACTOR VIII / VWF COMPLEX
ATE319817T1 (en) 1996-04-24 2006-03-15 Univ Michigan INACTIVATION-RESISTANT FACTOR VIII
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
AU2003227687B2 (en) 2002-04-29 2009-10-15 Stichting Sanquin Bloedvoorziening Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
HUE058897T2 (en) 2003-02-26 2022-09-28 Nektar Therapeutics Polymer-factor viii moiety conjugates
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EA008831B1 (en) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Glp-1 analog fusion proteins
CA2551916C (en) 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2821832T3 (en) 2004-11-12 2021-04-27 Bayer Healthcare Llc Site-directed modification of FVIII
EP1835938B1 (en) 2004-12-27 2013-08-07 Baxter International Inc. Polymer-von willebrand factor-conjugates
AU2006233638A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20080108147A (en) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 Pegylated factor viii
PL3896090T3 (en) 2006-06-14 2022-05-02 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP2486936A1 (en) 2007-06-13 2012-08-15 CSL Behring GmbH A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
US8575104B2 (en) 2008-06-24 2013-11-05 Csl Behring Gmbh Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
SG11201403764XA (en) 2012-01-12 2014-07-30 Biogen Idec Inc Chimeric factor viii polypeptides and uses thereof
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
WO2013160005A1 (en) 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
ES2657291T3 (en) * 2013-04-22 2018-03-02 Csl Ltd. A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge
JP2016522219A (en) 2013-06-12 2016-07-28 ノヴォ ノルディスク アー／エス Compounds suitable for the treatment of hemophilia
EP3152230B1 (en) 2014-06-06 2019-08-07 Octapharma AG Preparation comprising factor viii and von willebrand factor peptides
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor

Also Published As

Publication number Publication date
CN110381986A (en) 2019-10-25
US11890327B2 (en) 2024-02-06
DK3538134T3 (en) 2022-02-07
TW201828974A (en) 2018-08-16
EP3538134B1 (en) 2021-12-29
AU2017358865A1 (en) 2019-05-09
SG10201912768YA (en) 2020-02-27
KR20190073576A (en) 2019-06-26
WO2018087271A1 (en) 2018-05-17
CA3043397A1 (en) 2018-05-17
EP3538134A1 (en) 2019-09-18
ES2908008T3 (en) 2022-04-27
CN110381986B (en) 2023-08-18
US20210268071A1 (en) 2021-09-02
JP2020504082A (en) 2020-02-06

Similar Documents

Publication Publication Date Title
SG11201903954WA (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
SG11201805579SA (en) Recombinant igg fc multimers
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201900596XA (en) Cannabis composition
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201806992VA (en) Antibodies to tigit
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201811432WA (en) Rna for cancer therapy
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804038VA (en) Conditionally active heterodimeric polypeptides and methods of use thereof
SG11201903950UA (en) Truncated von willebrand factor polypeptides for treating hemophilia
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201805954WA (en) Methods for modulating intestinal microbiota
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201901576QA (en) Dosage regimen for a controlled-release pth compound
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201805755SA (en) Methods of administering hepcidin
SG11201805001UA (en) Method of treating influenza a
SG11201810157QA (en) Variant flavivirus envelope sequences and uses thereof